跨诊断互联网预防方案对青少年的疗效(EMPATIA研究):一项随机对照试验的研究方案
该随机对照试验计划在152名12-18岁具有亚临床精神症状但无当前或既往精神障碍的青少年中,比较8周引导式跨诊断互联网预防方案(EMPATIA)与常规照护的疗效,主要结局为干预后自评一般精神病理水平,并随访至12个月。
要点
- EMPATIA为8周引导式互联网方案,含8个模块,靶向重复负性思维、自我完美主义等6个跨诊断机制。
- 研究对象为12-18岁有亚临床症状但无当前或既往精神障碍的青少年,计划样本量152例。
- 主要结局为干预后自评一般精神病理水平,随访至12个月,并评估中介、调节因素及核心症状变化。
核心结论
- 该研究将评估EMPATIA跨诊断互联网预防方案对青少年的疗效、中介因素、调节因素及核心症状变化。
- 作者认为该方案可能有助于缩小青少年照护缺口、预防精神健康问题及长期促进心理健康。
研究设计与样本
- 随机对照试验,在一般人群样本中开展,计划纳入152名12-18岁有亚临床症状但无当前或既往精神障碍的青少年。
- 参与者随机分配至8周引导式EMPATIA方案组或常规照护对照组。
- EMPATIA方案含8个模块,靶向重复负性思维、自我完美主义、情绪调节、不确定性不耐受、拒绝敏感性和行为回避6个跨诊断机制。
- 在基线、8周后及6、9、12个月随访时填写在线自评问卷;基线和12个月随访时进行诊断性电话访谈。
主要发现
- 主要结局为干预后自评一般精神病理水平。
- 将在EMPATIA方案期间及之后评估干预特异性构念:动机、联盟、负性效应、满意度和依从性。
关键数值与推荐
- 计划样本量n=152,年龄12-18岁。
- 干预时长8周,含8个模块。
- 随访时间点为基线、8周后及6、9、12个月。
- 主要结局为干预后自评一般精神病理水平。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most mental disorders have their onset in adolescence. Preventive interventions during this period are important; however, help-seeking behavior is generally poor in this age group resulting in low treatment rates. Internet interventions are expected to be an effective, low-threshold, and scalable approach to overcome barriers to help-seeking, particularly for individuals experiencing subclinical symptoms. Internet-delivered indicated prevention seems promising as it targets individuals with minimal symptoms of mental disorders who might need care but are not help-seeking yet. Previous indicated prevention-approaches have mainly targeted specific risk-syndromes. However, this contradicts the increasing recognition of emerging psychopathology as a complex system characterized by co-occurrence and rapid shifts of subclinical symptoms cutting across diagnostic categories. Therefore, this study will investigate the efficacy, mediators, moderators, and core symptomatic changes of a transdiagnostic Internet-delivered indicated prevention program (EMPATIA program) for adolescents. METHODS: This randomized controlled trial (RCT) will be conducted in a general population sample (planned n = 152) of adolescents aged 12-18 years with subclinical symptoms but without any current or past mental disorder. Participants will be randomly assigned to the EMPATIA program or a care as usual (CAU) control condition. The 8-week guided EMPATIA program encompasses 8 modules targeting the following transdiagnostic mechanisms: repetitive negative thinking, self-perfectionism, emotion regulation, intolerance of uncertainty, rejection sensitivity, and behavioral avoidance. Participants will be asked to answer online self-report questionnaires at baseline, after 8 weeks, and at 6-, 9-, and 12-month follow-up. Diagnostic telephone interviews will be conducted at baseline and at 12-month follow-up. Additionally, intervention-specific constructs (motivation, alliance, negative effects, satisfaction, adherence) will be assessed during and after the EMPATIA program. The level of self-reported general psychopathology post-intervention is the primary outcome. DISCUSSION: Results will be discussed considering the potential of Internet interventions as a scalable, low-threshold option for indicated prevention in adolescents experiencing subclinical symptoms. The EMPATIA program introduces a novel Internet prevention program targeting six transdiagnostic mechanisms associated with various mental health outcomes. Thereby, this trial pursues a very timely and important topic because it may contribute to narrow the current care gap for adolescents, to prevent mental health problems and related negative consequences, and to promote mental health in the long-term. TRIAL REGISTRATION: The trial was approved by Swissmedic (Registration Number: 10001035, 08/22/2022) and the Ethics Committee of Bern (Registration Number: 2022-D0036, 08/22/2022). The trial was registered at ClinicalTrials.gov NCT05934019 on 07-03-2023.
引用
- Hirsig A, Häfeli XA, Schmidt SJ, et al. Efficacy of a transdiagnostic Internet prevention approach in adolescents (EMPATIA study): study protocol of a randomized controlled trial. Trials. 2024. PMID: 39118136. doi:10.1186/s13063-024-08241-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。